Haemonetics (NYSE: HAE) reported Q1 EPS of $1.14, $0.05 better than the analyst estimate of $1.09. Revenue for the quarter came in at $339 million versus the consensus estimate of $328.92 million.

For earnings history and earnings-related data on Haemonetics (HAE) click here.